The effect of recombinant human phospholipase D2(rhPLD2)in vivo was investigated on the secretion of serum glycosyl phosphatidylinositol-specific phospholipase D(GPI-PLD)in guinea pigs of chronic asthma．Ater treating the guinea pigs attacked by chronic asthma with rhPLD2,the GPI-PLD activity detection was canrried out by phase separation of human placental alkaline phosphatase in Triton X-114．Compared with the healthy guinea pigs(NS group),the serum GPI-PLD in the guinea pigs of chronic asthma are much higher than that of control groups,P≤0．01．Our results showed that rhPLD2 could significantly reduce the secretion of GPI-PLD when the guinea pigs were attacked by chronic asthma．

Objective:To study the biologic function of rhPLD2 mutation form.Methods:To adapt the guinea pig chronic asthma model was induced by OVA, the functions of rhPLD2 on PAF was observed through the assay of platelet congregating.Results:rhPLD2 remarkably reduced the lever of PAF in the serum of guinea pig chronic asthma model; compares with the NS group, the P

Aim To evaluate whether the combination of polypeptide AP25 and docetaxel is more efficient in treating experimental breast cancer,than either reagent used alone,and to offer suggestions for clinical use. Methods An experimental breast carcinoma model was set up to investigate the anti-tumor effects of AP25 and docetaxel combination.The Q value was caluculat-ed by Guinness rules and the anti-tumor effects of the combination of polypeptide AP25 and docetaxel were e-valuated.Results The treatment by the combination of polypeptide AP25 and docetaxel showed a better tumor inhibition rate.The combination of AP25 20 mg ·kg -1 and docetaxel 10 mg·kg -1 significantly inhibi-ted the tumor growth with 0.85 1.15,showing a synergistic effect.Conclusions The combination of AP25 and docetaxel can significantly in-hibit the tumor growth with a synergistic effect and de-crease the dose of chemotherapy.

mPEG-SC20k-HM-3 is a novel anti-angiogenesis peptide with integrin affinity. To investigate the anti-tumor activities of mPEG-SC20k-HM-3 and oxaliplatin(OXA)combination, a transplanted tumor model of human hepatocellular carcinoma SMMC-7721 in nude mice was established. Jin′s formula to evaluate the combination effect was used. Data suggested that the anti-tumor activities of combined groups were better than those of single drug(P< 0. 05). Inhibition rate of group 8(OXA 7. 5 mg/kg and mPEG-SC20k-HM-3 73. 4 mg/kg)was 84. 6%, which showed remarkable superiority to group 3(OXA 7. 5 mg/kg)and group 4(mPEG-SC20k-HM-3 73. 4 mg/kg). The Q of group 8 was 1. 164(> 1. 15). This combination had synergistic effect. Combination of mPEG-SC20k-HM-3 and oxaliplatin is a method of inhibiting hepatocellular carcinoma.